Sophie Demeret

Sophie Demeret

Auto-generated profile, based on publicly available information

Sophie Demeret

Neuro‐Intensive Care Unit AP‐HP, Sorbonne Université, Hôpital de la Pitié‐Salpêtrière Paris France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Radiology
Verified
Journal Article
Closed access
LCLydia Chougar
Lydia Chougar
NSNatalia Shor
Natalia Shor
NWNicolas Weiss
Nicolas Weiss
DGDamien Galanaud
Damien Galanaud
DLDelphine Leclercq
Delphine Leclercq
FGFor the CoCo Neurosciences Study Group
For the CoCo Neurosciences Study Group
Background This study provides a detailed imaging assessment in a large series of COVID-19 patients with neurological manifestations. Purpose To review the MRI findings associated with acute neurol...

21 February 2022 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
AHAurélie Hanin
Aurélie Hanin
Jérôme DENISJérôme DENIS
Jérôme DENIS
VFValerio Frazzini
Valerio Frazzini
LCLouis Cousyn
Louis Cousyn
FIFrançoise Imbert-Bismut
Françoise Imbert-Bismut
VNVincent Navarro
Vincent Navarro

1 July 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
MGMartin Guillemaud
Martin Guillemaud
MCMario Chavez
Mario Chavez
Firas KobeissyFiras Kobeissy
Firas Kobeissy
AVAnnamaria Vezzani
Annamaria Vezzani
AJAnthony D. Jimenez
Anthony D. Jimenez
AHAurélie Hanin
Aurélie Hanin
Emerging evidence suggests that immune dysregulation plays a pivotal role in triggering cryptogenic new-onset refractory status epilepticus (c-NORSE), prompting a consensus on early initiation of immunotherapy. However, despite similar timing of administration, responses to immunotherapies have been varied and unpredictable, suggesting the presence of heterogeneous underlying mechanisms. The aim of this study was to identify distinct inflammatory response subtypes in patients with c-NORSE by analyzing their cytokine profiles. Insights into underlying mechanisms were sought to understand the pathophysiology and guide personalized therapies to improve patient outcomes. Sixty-two patients with c-NORSE were included. A comprehensive panel of 96 cytokines was analyzed in serum samples. Patients were clustered based on their cytokine profiles using the Louvain algorithm, an unsupervised graph-based clustering method. The identified clusters of patients were compared regarding cytokine levels and clinical features. Protein pathway analysis was used to explore the biological relevance of the inflammatory markers within each cluster. Patients with c-NORSE were compared with control patients (n = 18) and patients with other forms of refractory SE (n = 45). Compared with controls, patients with c-NORSE exhibited significant differences in 33 cytokines. Pathway analysis revealed dysregulations in chemotaxis and neutrophil recruitment and migration, highlighting the importance of innate immunity in patients with c-NORSE. Within the c-NORSE cohort, 3 clusters of patients emerged: cluster A, lacking specific inflammatory markers; cluster B, with a much stronger innate-immunity cytokine-driven inflammatory response compared with clusters A and C; and cluster C, defined by dysregulated autoimmune processes. Notably, patients in cluster B showed a statistically significant elevation of innate immune-related proinflammatory cytokines associated with leukocyte recruitment and degranulation. By contrast, those in cluster C showed activation of Janus kinase signal transducer and activator of transcription (JAK-STAT) pathways, suggesting autoimmune mechanisms. Patients in clusters B and C demonstrated varied responses to immunotherapies, with cluster C patients showing favorable outcomes after multiple immunotherapies. The identification of distinct inflammatory subgroups in c-NORSE suggests that variations in the underlying immune mechanisms contribute to differential treatment responses. These findings underscore the importance of personalized therapeutic strategies, potentially targeting specific inflammatory pathways, to optimize clinical outcomes in this challenging condition.

20 December 2012 in Gene
Verified
Journal Article
Open access
PDF file
LDLinda Dainese
Linda Dainese
MMMarie-Lorraine Monin
Marie-Lorraine Monin
SDSophie Demeret
Sophie Demeret
GBGuy Brochier
Guy Brochier
RFRoseline Froissart
Roseline Froissart
FMFanny MOCHEL
Fanny MOCHEL
Background: A 45-year old woman of Cambodian ethnic background presented with fatal respiratory failure due to a severe diaphragmatic dysfunction. Two years before, she had developed early onset of urinary symptoms. Methods and results Neuroimaging showed atrophy of the spine and medulla as well as a leukodystrophy affecting both supra- and infra-tentorial regions. At autopsy, polyglucosan bodies (PB) were seen in several peripheral tissues, including the diaphragm, and nervous tissues such as peripheral nerves, cerebral white matter, basal ganglia, hippocampus, brainstem and cerebellum. Immunohistochemistry and electron microscopy of the brain revealed an exclusive astrocytic localization of the PB. The diagnosis of adult polyglucosan body disease (APBD) was confirmed by enzymatic and molecular studies. Conclusion: Storage of abnormal glycogen in astrocytes is sufficient to cause the leukodystrophy of APBD. Since brain glycogen is almost exclusively metabolized in astrocytes, this observation sheds light on the pathophysiology of APBD. In addition, this is the first report of an APBD patient presenting with a subacute diaphragmatic failure.

1 May 2024 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
FLFlorian Lamblin
Florian Lamblin
JKJeroen Kerstens
Jeroen Kerstens
SMSergio Muñiz-Castrillo
Sergio Muñiz-Castrillo
AVAlberto Vogrig
Alberto Vogrig
DGDavid Goncalves
David Goncalves
JHJerome Honnorat
Jerome Honnorat
While patients with paraneoplastic autoimmune encephalitis (AE) with gamma-aminobutyric-acid B receptor antibodies (GABABR-AE) have poor functional outcomes and high mortality, the prognosis of nonparaneoplastic cases has not been well studied. Patients with GABABR-AE from the French and the Dutch Paraneoplastic Neurologic Syndromes Reference Centers databases were retrospectively included and their data collected; the neurologic outcomes of paraneoplastic and nonparaneoplastic cases were compared. Immunoglobulin G (IgG) isotyping and human leukocyte antigen (HLA) genotyping were performed in patients with available samples. A total of 111 patients (44/111 [40%] women) were enrolled, including 84 of 111 (76%) paraneoplastic and 18 of 111 (16%) nonparaneoplastic cases (cancer status was undetermined for 9 patients). Patients presented with seizures (88/111 [79%]), cognitive impairment (54/111 [49%]), and/or behavioral disorders (34/111 [31%]), and 54 of 111 (50%) were admitted in intensive care unit (ICU). Nonparaneoplastic patients were significantly younger (median age 54 years [range 19-88] vs 67 years [range 50-85] for paraneoplastic cases, p < 0.001) and showed a different demographic distribution. Nonparaneoplastic patients more often had CSF pleocytosis (17/17 [100%] vs 58/78 [74%], p = 0.02), were almost never associated with KTCD16-abs (1/16 [6%] vs 61/70 [87%], p < 0.001), and were more frequently treated with second-line immunotherapy (11/18 [61%] vs 18/82 [22%], p = 0.003). However, no difference of IgG subclass or HLA association was observed, although sample size was small (10 and 26 patients, respectively). After treatment, neurologic outcome was favorable (mRS ≤2) for 13 of 16 (81%) nonparaneoplastic and 37 of 84 (48%) paraneoplastic cases (p = 0.03), while 3 of 18 (17%) and 42 of 83 (51%) patients had died at last follow-up (p = 0.008), respectively. Neurologic outcome no longer differed after adjustment for confounding factors but seemed to be negatively associated with increased age and ICU admission. A better survival was associated with nonparaneoplastic cases, a younger age, and the use of immunosuppressive drugs. Nonparaneoplastic GABABR-AE involved younger patients without associated KCTD16-abs and carried better neurologic and vital prognoses than paraneoplastic GABABR-AE, which might be due to a more intensive treatment strategy. A better understanding of immunologic mechanisms underlying both forms is needed.

1 March 2021 in Neurophysiologie Clinique
Verified
Journal Article
Closed access
AHAurélie Hanin
Aurélie Hanin
SDSophie Demeret
Sophie Demeret
VNVi-Huong Nguyen-Michel
Vi-Huong Nguyen-Michel
VLVirginie Lambrecq
Virginie Lambrecq
VNVincent Navarro
Vincent Navarro